Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2008.16.7981 on April 20 2009

Journal of Clinical Oncology, Vol 27, No 18 (June 20), 2009: pp. 3000-3006
© 2009 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Google Scholar
Right arrow Articles by Krauter, J.
Right arrow Articles by Ganser, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Krauter, J.
Right arrow Articles by Ganser, A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Leukemia and Bone Marrow Transplantation

Prognostic Factors in Adult Patients up to 60 Years Old With Acute Myeloid Leukemia and Translocations of Chromosome Band 11q23: Individual Patient Data–Based Meta-Analysis of the German Acute Myeloid Leukemia Intergroup

Jürgen Krauter, Katharina Wagner, Irina Schäfer, Rolf Marschalek, Claus Meyer, Gerhard Heil, Markus Schaich, Gerhard Ehninger, Dietger Niederwieser, Rainer Krahl, Thomas Büchner, Cristina Sauerland, Brigitte Schlegelberger, Konstanze Döhner, Hartmut Döhner, Richard F. Schlenk, Arnold Ganser

From the Departments of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation and Cellular and Molecular Pathology, Hannover Medical School, Hannover; Institute of Pharmaceutical Biology/Diagnostic Center of Acute Leukemia/Zentrum für Arzneimittelforschung, Entwicklung, und Sicherheit, Johann Wolfgang Goethe University, Biocenter, Frankfurt am Main; Medizinische Klinik und Poliklinik I, Universitätsklinikum C.G. Carus, Dresden; Department of Hematology and Oncology, University of Leipzig, Leipzig; Universitätsklinikum Münster, Medizinische Klinik und Poliklinik A; Department of Medical Informatics and Biomathematics, University of Münster, Münster; and Department Internal Medicine III, University of Ulm, Ulm, Germany.

Corresponding author: Jürgen Krauter, MD, Department Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School, Carl-Neuberg-Str 1, D-30625 Hannover, Germany; e-mail: Krauter.Juergen{at}MH-Hannover.de.

Purpose To identify risk factors for induction success and overall survival (OS) and relapse-free survival (RFS) and to evaluate the impact of allogeneic stem-cell transplantation (alloSCT) in adult patients up to 60 years old with acute myeloid leukemia (AML) and reciprocal translocations involving chromosome band 11q23 [t(11q23)].

Patients and Methods An individual patient data-based meta-analysis was performed on 180 adult patients with AML and t(11q23). These patients were identified by cytogenetics and/or molecular techniques and treated within eight prospective multicenter trials of the German AML Intergroup. The median follow-up time was 53 months.

Results Complete remission rate was 71%. Favorable factors for induction success were the presence of a t(9;11), t(11q23) as a sole aberration, and de novo leukemia. OS rate at 4 years was 29%. Translocations other than t(9;11), platelets less than the median, secondary leukemia, and peripheral blasts greater than the median were adverse risk factors for OS. RFS rate at 4 years was 29%. The presence of a t(6;11) and peripheral blasts greater than the median had a negative impact on RFS. Three risk groups for OS and RFS could be defined by the combination of these factors with 4-year OS rates of 50%, 28%, and 5% and 4-year RFS rates of 37%, 26%, and 5%. An alloSCT from matched related or unrelated donors in first complete remission was beneficial, especially in t(6;11)-negative patients.

Conclusion Risk stratification of AML patients with reciprocal translocations of chromosome band 11q23 is feasible based on the translocation partner and clinical parameters.

Supported in part by Grant No. 01GI0378 from the Bundesministerium für Bildung und Forschung (Kompetenz-netz "Akute und Chronische Leukämien"), Germany.

Presented in part at the 48th Annual Meeting of the American Society of Hematology, December 9-12, 2006, Orlando, FL; and at the 49th Annual Meeting of the American Society of Hematology, December 8-11, 2007, Atlanta, GA.

Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
BloodHome page
B. J. Lange
T(11q23): brand necessary
Blood, September 17, 2009; 114(12): 2365 - 2366.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2009 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online